Jang Jong-wook, CEO of ENCell, delivered an online oral presentation at the 12th International Symposium hosted by the Cell and Gene Therapy Institute of Samsung Medical Center (SMC) and the Gene and Cell Therapy Institute of Samsung Advanced Institute of Hybrid Science and Technology (SAIHST).

The event, titled "Pathways to Clinical Application: Mesenchymal Stem Cell (MSC) and Adeno-Associated Virus (AAV)-based Approaches for Neuromuscular Disorders," highlighted advances in cell and gene therapies.

During his presentation, Jang introduced ENCell's proprietary ENCT (ENCell Technology) platform and provided updates on EN001-CMT 1A, a mesenchymal stem cell therapy candidate for Charcot-Marie-Tooth disease type 1A.

He also shared data from research into CMT 1E and outlined future development plans. In February, EN001 was granted orphan drug designation by the U.S. FDA for Charcot-Marie-Tooth disease.

Jang also discussed global trends in AAV platform development and shared progress on ENCell’s AAV technologies targeting tissue-specific applications, including muscle and ocular indications.

“It was a meaningful opportunity to showcase ENCell's novel drug pipeline and AAV platform at an international symposium that leads the field of cell and gene therapy in Korea,” said Jang. “We will continue to actively participate in major symposiums, conferences, and congresses to promote ENCell’s technology and drive sustainable growth.”